- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07759154
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
A Phase 3b, Multicenter, Open-label, Single-arm Trial to Evaluate the Efficacy and Safety of Orally Administered Centanafadine QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: otsuka-professionalservices@otsuka-us.com
Lieux d'étude
-
-
Florida
-
Gainesville, Florida, États-Unis, 32607
- Recrutement
- Sarkis Clinical Trials - Gainesville
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Sarkis
-
Jacksonville, Florida, États-Unis, 32256
- Recrutement
- CNS Healthcare - Jacksonville (Clinical Neuroscience Solutions - Jacksonville)
-
Chercheur principal:
- Jones
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Maitland, Florida, États-Unis, 32751
- Recrutement
- Accel Research Sites-Maitland
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Marraffino
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70125
- Recrutement
- Nola Research Works
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Hebert
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02132
- Recrutement
- Boston Clinical Trials
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Mezhebovsky
-
Watertown, Massachusetts, États-Unis, 02472
- Recrutement
- Adams Clinical - Watertown
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Rutrick
-
-
Missouri
-
Saint Charles, Missouri, États-Unis, 63304
- Recrutement
- St. Charles Psychiatric Associates/Midwest Research Group
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Mattingly
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89128
- Recrutement
- Center for Psychiatry and Behavioral Medicine. Inc.
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Childress
-
-
New Jersey
-
Cherry Hill, New Jersey, États-Unis, 08002
- Recrutement
- Center for Emotional Fitness
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Corcoran
-
-
New York
-
New York, New York, États-Unis, 10128
- Recrutement
- The Medical Research Network, LLC
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Careri
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45215
- Recrutement
- Patient Priority Clinical Trials
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Popovitz
-
-
Oregon
-
Portland, Oregon, États-Unis, 97210
- Recrutement
- Summit Research Network
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Essink
-
-
Texas
-
Austin, Texas, États-Unis, 78737
- Recrutement
- Donald J. Garcia, Jr, MD, PA
-
Chercheur principal:
- Garcia
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Bellaire, Texas, États-Unis, 77401
- Recrutement
- Houston Clinical Trials LLC
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Katic
-
Houston, Texas, États-Unis, 77089
- Recrutement
- Kaleidoscope Clinical Research
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Higgins
-
-
Washington
-
Everett, Washington, États-Unis, 98201
- Recrutement
- Core Clinical Research
-
Contact:
- Otsuka Call Center
- Numéro de téléphone: 844-687-8522
- E-mail: Otsuka-ProfessionalServices@otsuka-us.com
-
Chercheur principal:
- Knutson
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
- Primary diagnosis of ADHD per the Adult ADHD Clinical Diagnostic Scale (ACDS).
- Adult ADHD Investigator Symptom Rating Scale (AISRS) total score of ≥ 28 at baseline.
- Symptoms of ED as determined by the WRAADDS-ED subscale score ≥ 7 at baseline.
- CGI-S-ADHD rating ≥ 4 (at least moderate severity) at baseline.
Exclusion Criteria
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for a lifetime diagnosis of bipolar and related disorders, schizophrenia spectrum and other psychotic disorders, borderline and antisocial personality disorders, neurocognitive disorders, autism spectrum disorder, or intellectual disability.
- DSM-5 criteria for a current diagnosis of major depressive disorder, post-traumatic stress disorder, any substance use disorder, untreated/unstable obstructive sleep apnea, eating disorders, or obsessive compulsive disorder.
- Any other current DSM-5 comorbid psychiatric disorder identified by the Mini International Neuropsychiatric Interview (MINI) or any medical condition that, in the judgment of the investigator, could be expected to require treatment with medications prohibited in this trial that cannot be safely discontinued with completion of an appropriate washout, could confound efficacy or safety assessments, or be the primary driver of ED.
- Presence of an unstable or uncontrolled medical condition that, in the opinion of the investigator, could pose a safety risk to the participant or could manifest with psychiatric symptoms (eg, thyroid disease).
- In the clinical opinion of the investigator, the participant has not derived significant therapeutic benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and methylphenidate, or amphetamine and atomoxetine) given with an acceptable dose and duration during adulthood (aged 18 years or older).
- Current use of prohibited psychotropic medications that cannot be discontinued within 7 to 28 days prior to enrollment.
- Any disorder that is the primary focus of treatment other than ADHD.
- Evidence of current substance use disorder or history in the past 12 months.
- History of any prior exposure to centanafadine.
- Participated in other clinical trials involving investigational drugs within 180 days prior to screening or participated in more than 2 interventional clinical trials involving investigational drugs within the past year.
- Have an allergy to the IMP or any component of the IMP.
Note: Other protocol-specified inclusion/exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Centanafadine XR
Participants will receive centanafadine XR capsule 328.8 milligrams (mg), orally, QD, for 8 weeks. |
Oral capsules
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale Emotional Dysregulation (WRAADDS-ED) Subscale Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Clinical Global Impressions-Severity Scale for Attention-Deficit/Hyperactivity Disorder (CGI-S-ADHD) Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) T-score for the Global Executive Composite (GEC) Scale
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Behavioral Regulation Index (BRI) Scale
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Metacognition Index (MI) Scale
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties in Emotion Regulation Scale (DERS) Total Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Nonacceptance of Emotional Responses (NONACCEPT) DERS Subscale Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties Engaging in Goal-Directed Behavior (GOALS) DERS Subscale Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Impulse Control Difficulties (IMPULSE) DERS Subscale Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Awareness (AWARE) DERS Subscale Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Limited Access to Emotion Regulation Strategies (STRATEGIES) DERS Subscale Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Clarity (CLARITY) DERS Subscale Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Attention-Deficit/Hyperactivity Disorder Symptoms, Executive Function Deficits, and Emotional Dyscontrol as Assessed by the Adult ADHD Self-Report Scale (ASRS) Score
Délai: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Number of Participants With Adverse Events
Délai: Up to Week 9
|
Up to Week 9
|
|
Number of Participants With Suicidal Ideation or Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Délai: Up to Week 9
|
Up to Week 9
|
Collaborateurs et enquêteurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 405-201-00231
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Délai de partage IPD
Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Critères d'accès au partage IPD
Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .